CP and COVID-19: Depletion or functional impairment of T cells, for example following treatment with disease modifying antirheumatic drugs (DMARDs) (37) may account for the failure of CP administered as a single agent in B cell-depleted individuals with RDs and explain why in this population rituximab should be considered a risk factor for unfavorable outcome with a high rate of severe COVID-19 leading to a high mortality rate (23.1%) (38).